Clinical Trial Update: Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study tested bevacizumab with erlotinib in patients with metastatic or unresectable biliary tract cancers (cholangiocarcinoma of the extrahepatic bile…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder | Phase 2 | Status: COMPLETED | Results posted: 2013-05-20